Literature DB >> 34235673

A Multistress Model for High Throughput Screening Against Nonreplicating Mycobacterium tuberculosis.

Ben Gold1, Thulasi Warrier2, Carl Nathan3.   

Abstract

Models of nonreplication help us understand the biology of persistent Mycobacterium tuberculosis. High throughput screening (HTS) against nonreplicating M. tuberculosis may lead to identification of tool compounds that affect pathways on which bacterial survival depends in such states and to development of drugs that can overcome phenotypic resistance to conventional antimycobacterial agents, which are mostly active against replicating M. tuberculosis. We describe a multistress model of nonreplication that mimics some of the microenvironmental conditions that M. tuberculosis faces in the host as adapted for HTS. The model includes acidic pH, mild hypoxia, a flux of nitric oxide, and other reactive nitrogen intermediates arising from nitrite at low pH and low concentrations of a fatty acid (butyrate) as a carbon source.

Entities:  

Keywords:  Acidic pH; Antibiotics; Fatty acids; High-throughput screening; Hypoxia; Mycobacterium tuberculosis; Nitric oxide; Nonreplication; Phenotypic tolerance; Reactive nitrogen species

Year:  2021        PMID: 34235673     DOI: 10.1007/978-1-0716-1460-0_27

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  38 in total

1.  Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates.

Authors:  Zhifang Xie; Noman Siddiqi; Eric J Rubin
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

2.  Dual-Pharmacophore Pyrithione-Containing Cephalosporins Kill Both Replicating and Nonreplicating Mycobacterium tuberculosis.

Authors:  Landys Lopez Quezada; Kelin Li; Stacey L McDonald; Quyen Nguyen; Andrew J Perkowski; Cameron W Pharr; Ben Gold; Julia Roberts; Kathrine McAulay; Kohta Saito; Selin Somersan Karakaya; Prisca Elis Javidnia; Esther Porras de Francisco; Manuel Marin Amieva; Sara Palomo Dı Az; Alfonso Mendoza Losana; Matthew Zimmerman; Hsin-Pin Ho Liang; Jun Zhang; Veronique Dartois; Stéphanie Sans; Sophie Lagrange; Laurent Goullieux; Christine Roubert; Carl Nathan; Jeffrey Aubé
Journal:  ACS Infect Dis       Date:  2019-06-11       Impact factor: 5.084

Review 3.  TB drug development: immunology at the table.

Authors:  Carl Nathan; Clifton E Barry
Journal:  Immunol Rev       Date:  2015-03       Impact factor: 12.988

4.  Identification of novel inhibitors of nonreplicating Mycobacterium tuberculosis using a carbon starvation model.

Authors:  Sarah Schmidt Grant; Tomohiko Kawate; Partha P Nag; Melanie R Silvis; Katherine Gordon; Sarah A Stanley; Edward Kazyanskaya; Raymond Nietupski; Aaron Golas; Michael Fitzgerald; Sanghyun Cho; Scott G Franzblau; Deborah T Hung
Journal:  ACS Chem Biol       Date:  2013-08-13       Impact factor: 5.100

5.  Nutrient-starved, non-replicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability.

Authors:  Martin Gengenbacher; Srinivasa P S Rao; Kevin Pethe; Thomas Dick
Journal:  Microbiology       Date:  2009-10-01       Impact factor: 2.777

6.  Selective killing of nonreplicating mycobacteria.

Authors:  Ruslana Bryk; Benjamin Gold; Aditya Venugopal; Jasbir Singh; Raghu Samy; Krzysztof Pupek; Hua Cao; Carmen Popescu; Mark Gurney; Srinivas Hotha; Joseph Cherian; Kyu Rhee; Lan Ly; Paul J Converse; Sabine Ehrt; Omar Vandal; Xiuju Jiang; Jean Schneider; Gang Lin; Carl Nathan
Journal:  Cell Host Microbe       Date:  2008-03-13       Impact factor: 21.023

7.  N,C-Capped dipeptides with selectivity for mycobacterial proteasome over human proteasomes: role of S3 and S1 binding pockets.

Authors:  Gang Lin; Tamutenda Chidawanyika; Christopher Tsu; Thulasi Warrier; Julien Vaubourgeix; Christopher Blackburn; Kenneth Gigstad; Michael Sintchak; Lawrence Dick; Carl Nathan
Journal:  J Am Chem Soc       Date:  2013-06-25       Impact factor: 15.419

8.  A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis.

Authors:  Puiying A Mak; Srinivasa P S Rao; Mai Ping Tan; Xiuhua Lin; Jason Chyba; Joann Tay; Seow Hwee Ng; Bee Huat Tan; Joseph Cherian; Jeyaraj Duraiswamy; Pablo Bifani; Vivian Lim; Boon Heng Lee; Ngai Ling Ma; David Beer; Pamela Thayalan; Kelli Kuhen; Arnab Chatterjee; Frantisek Supek; Richard Glynne; Jun Zheng; Helena I Boshoff; Clifton E Barry; Thomas Dick; Kevin Pethe; Luis R Camacho
Journal:  ACS Chem Biol       Date:  2012-04-25       Impact factor: 5.100

9.  Inhibitors selective for mycobacterial versus human proteasomes.

Authors:  Gang Lin; Dongyang Li; Luiz Pedro Sorio de Carvalho; Haiteng Deng; Hui Tao; Guillaume Vogt; Kangyun Wu; Jean Schneider; Tamutenda Chidawanyika; J David Warren; Huilin Li; Carl Nathan
Journal:  Nature       Date:  2009-09-16       Impact factor: 49.962

Review 10.  Kunkel Lecture: Fundamental immunodeficiency and its correction.

Authors:  Carl Nathan
Journal:  J Exp Med       Date:  2017-07-12       Impact factor: 14.307

View more
  2 in total

Review 1.  Anti-tuberculosis treatment strategies and drug development: challenges and priorities.

Authors:  Véronique A Dartois; Eric J Rubin
Journal:  Nat Rev Microbiol       Date:  2022-04-27       Impact factor: 78.297

2.  In Vitro and In Vivo Inhibition of the Mycobacterium tuberculosis Phosphopantetheinyl Transferase PptT by Amidinoureas.

Authors:  Samantha Ottavi; Sarah M Scarry; John Mosior; Yan Ling; Julia Roberts; Amrita Singh; David Zhang; Laurent Goullieux; Christine Roubert; Eric Bacqué; H Rachel Lagiakos; Jeremie Vendome; Francesca Moraca; Kelin Li; Andrew J Perkowski; Remya Ramesh; Matthew M Bowler; William Tracy; Victoria A Feher; James C Sacchettini; Ben S Gold; Carl F Nathan; Jeffrey Aubé
Journal:  J Med Chem       Date:  2022-01-19       Impact factor: 8.039

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.